Results 161 to 170 of about 6,428 (208)
Some of the next articles are maybe not open access.
Rimonabant—A Selective CB1 Antagonist
Annals of Pharmacotherapy, 2005OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of rimonabant, a new selective cannabinoid receptor antagonist. DATA SOURCES: Primary literature and review articles were obtained via a MEDLINE ...
Steven Thomas, Boyd +1 more
exaly +3 more sources
Drugs, 2006
Rimonabant is the first of a new class of selective cannabinoid receptor-1 blockers. It reduces the overactivity of the endocannabinoid system, improving lipid and glucose metabolism and regulating food intake and energy balance. In four randomised, double-blind clinical trials in overweight or obese adults with or without type 2 diabetes and/or ...
Sheridan, Henness +2 more
+6 more sources
Rimonabant is the first of a new class of selective cannabinoid receptor-1 blockers. It reduces the overactivity of the endocannabinoid system, improving lipid and glucose metabolism and regulating food intake and energy balance. In four randomised, double-blind clinical trials in overweight or obese adults with or without type 2 diabetes and/or ...
Sheridan, Henness +2 more
+6 more sources
Rimonabant: The first therapeutically relevant cannabinoid antagonist
Life Sciences, 2005 The present paper synthetically reviews the multiple experimental lines of evidence indicating the ability of the prototypic cannabinoid CB1 receptor antagonist, rimonabant (also known as SR 141716), to suppress the reinforcing/rewarding properties of ...
Giancarlo Colombo, Mauro A M Carai
exaly +2 more sources
Rimonabant: A Cannabinoid Receptor Type 1 Blocker for Management of Multiple Cardiometabolic Risk Factors [PDF]
Journal of the American College of Cardiology, 2006 Rimonabant is a first selective blocker of the cannabinoid receptor type 1 (CB1) being developed for the treatment of multiple cardiometabolic risk factors, including abdominal obesity and smoking.
Christopher Cannon
exaly +2 more sources
Rimonabant for overweight or obesity
Cochrane Database of Systematic Reviews, 2006Worldwide, the prevalence of obesity and overweight in industrialized countries and in a substantial number of developing countries is increasing at an alarming rate. Rimonabant is a selective cannabinoid-1 receptor antagonist that has been investigated for its efficacy in reducing body weight and associated risk factors in obese people.
C, Curioni, C, André
openaire +2 more sources
Journal of Pharmaceutical Negative Results, 2011
Rapidly rising prevalence of obesity and health care cost of its complications necessities need for highly efficacious and safe antiobesity drugs. As most old antiobesity drugs had moderate efficacy, severe toxicity and some of them very costly. Rimonabant, CB1 receptor antagonist was introduced with high expectations.
SuyogS Jain +3 more
openaire +1 more source
Rapidly rising prevalence of obesity and health care cost of its complications necessities need for highly efficacious and safe antiobesity drugs. As most old antiobesity drugs had moderate efficacy, severe toxicity and some of them very costly. Rimonabant, CB1 receptor antagonist was introduced with high expectations.
SuyogS Jain +3 more
openaire +1 more source